As of 2008, more than 33 million adults and children have been estimated to be living with human immunodeficiency virus (HIV). Among them are rare patients (<0.5%) who have remained clinically well without antiretroviral therapy after almost 20 years of infection. They maintain stable CD4 cell counts and suppressed HIV replication to levels comparable with those measured in patients receiving combination antiretroviral therapy. No known epidemiologic or behavioral factors are predictive of untreated, nonprogressive HIV infection; however, host genetics and immune response factors, most specifically HLA antigen class I–restricted HIV-specific CD8 T cells, appear to be primarily responsible for this remarkable phenotype in a majority of these individuals. These patients offer hope that durable control of HIV infection is possible and can provide important insight to inform the development of the next generation of HIV/AIDS vaccines and immune-based therapies. This article reviews clinical features of these unique patients and discusses them in the context of nonprogressors enrolled in other cohorts. Potential mechanisms underlying nonprogressive HIV infection and scientific discoveries, facilitated by the participation of these patients in clinical trials, of relevance to the design of an efficacious HIV/AIDS vaccine are also highlighted.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
CD4 cell counts and human immunodeficiency virus 1 (HIV-1) RNA levels are shown for the 2 patients described in the introductory text. Standard viral load testing (branched DNA, version 1; Chiron Corp, Emeryville, California) with a detection limit of 10 000 copies/mL was replaced in 1996 with an assay (ultrasensitive branched DNA, version 2; Chiron Corp) possessing a detection limit of 500 copies/mL through 1998, which preceded a newer-generation ultrasensitive assay (ultrasensitive branched DNA, version 3; Bayer Diagnostics, Tarrytown, New York) with a lower threshold of 50 copies/mL. Arrowheads refer to transient episodes of detectable viremia for patients 1 and 2. Anti–hepatitis C virus therapy, with interferon alfa-2b and ribavirin, is denoted at the top of panel A.
CD4 cell counts and human immunodeficiency virus 1 (HIV-1) RNA levels are shown for the patient described in the text (“Patient Characteristics” section). Standard viral load testing (branched DNA, version 1) with a detection limit of 10 000 copies/mL was replaced in 1996 with an assay (ultrasensitive branched DNA, version 2) possessing a detection limit of 500 copies/mL through 1998, which preceded an ultrasensitive assay (branched DNA, version 3) with a lower threshold of 50 copies/mL. Markers at the top of the plot indicate the 3-month period of anti–hepatitis C virus (HCV) therapy with interferon alfa-2a and ribavirin as well as antiretroviral therapy with emtricitabine, tenofovir, and raltegravir initiated in 2009.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 42
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.